24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
The Oxford PharmaGenesis Patient Engagement Team was lucky enough to attend the World Orphan Drug Congress Europe earlier in November. The virtual conference provided invaluable insights into hot topics and current issues for rare diseases. Of much interest to our team were patient centricity, initiatives working with patient groups/advocates and, specifically, discussions around access and…
Oxford PharmaGenesis is proud to support CISCRP in a new educational initiative to increase awareness and understanding of clinical research among minority urban communities. We have collaborated with CISCRP to sponsor an advertisement that highlights the key importance of diversity among participants in clinical studies in order to discover treatments that are effective for everyone….
The annual World Pharma Pricing Market Access & Evidence congress was held on 23–25 September 2020 for the first time in a virtual environment, and was attended by members of our Value Demonstration Practice.
Mental health for all. Greater investment – greater access. Everyone, everywhere. Oxford PharmaGenesis is committed to ensuring good mental health and well-being for all of its employees, offering access to support services, training and other valuable resources. We also host a team of trained Mental Health First Aiders (MHFAs) who serve as a point of…
Oxford PharmaGenesis was delighted to attend the recent eyeforpharma Patient Summit 2020 earlier this month. As part of the ‘new normal’, the meeting this year was virtual, and content was available on demand. This allowed multiple members of the Patient Engagement Team to attend and gain insights on the latest in the patient engagement field….
Alan Thomas is a patient advocate for rare diseases, and ataxia in particular. He is known as the ‘rare disease warrior’ and, as a patient with a life-limiting rare disease, he can convey the patient engagement message from his point of view on all issues regarding the wellbeing of patients.
